Results On average, you can expect a gradual weight loss of 1-2 pounds/week while following a medical weight loss plan
Marketed as Egrifta, it was approved in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy
As an oral preparation for research use, the analytical method for 5amino1mq capsules focuses on the accurate determination of active ingredient content and control of impurity limits, ensuring the purity and stability of the preparation to meet research and quality control requirements
In naturally aged mouse models (1820 months old), daily oral administration of 5-amino-1mq capsules for 12 consecutive weeks significantly reduced NNMT activity and increased NAD+ levels in various tissues (liver, kidney, adipose tissue), along with markedly elevated expression of SIRT1 and SIRT3 proteins
It is not intended for human or veterinary use, clinical trials, or diagnostic purposes